加载中
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
前收盘价
US$2.14
−US$0.07 · -3.17%
盘中时间采用ET。市场数据可能有所延迟。
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
日内区间
当前US$2.14
52周区间
当前US$2.14
盘中时间采用ET。市场数据可能有所延迟。
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
日内区间
当前US$2.14
52周区间
当前US$2.14
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | — | — | 117.6万 USD | 184万 USD | 125.7万 USD |
| 销货成本 | — | 35.2万 USD | 88.9万 USD | 154.1万 USD | 130.3万 USD |
| 毛利 | — | −35.2万 USD | 28.7万 USD | 29.9万 USD | −4.6万 USD |
| 研究与开发 | 313.1万 USD | 131.3万 USD | 165.5万 USD | 173万 USD | 87万 USD |
| 销售、一般及管理费用 | 476.7万 USD | 275.4万 USD | 687.7万 USD | 866.7万 USD | 471.7万 USD |
| 营业费用 | 789.8万 USD | 406.4万 USD | 853.2万 USD | 1039.7万 USD | 558.7万 USD |
| 利息收入 | 2.3万 USD | 6000 USD | 1000 USD | 2000 USD | — |
| 利息支出 | 14.6万 USD | — | — | — | 182.3万 USD |
| 折旧和摊销 | 5000 USD | 35.2万 USD | 18.2万 USD | 17.4万 USD | 2.4万 USD |
| 营业利润 | −789.8万 USD | −441.6万 USD | −824.5万 USD | −1009.8万 USD | −563.3万 USD |
| 净利润 | −887.8万 USD | −565.5万 USD | −824.4万 USD | −1009.6万 USD | −849.4万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月31日 | 1:25 | — | — |
股票拆分 | 2016年7月20日 | 1:10 | — | — |
已生效 2026年8月31日
1:25
已生效 2016年7月20日
1:10
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
